Posted by Michael Wonder on 14 May 2021
ICER releases draft evidence report on therapies for atopic dermatitis
14 May 2021 - Public comment period now open until 11 June 2021; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of the following therapies for atopic dermatitis:
- abrocitinib (Pfizer)
- tralokinumab (LEO Pharma)
- baricitinib (Olumiant, Eli Lilly, Incyte)
- upadacitinib (Rinvoq, AbbVie)
- ruxolitinib phosphate (Incyte)
This preliminary draft marks the midpoint of ICER’s eight month process of assessing these treatments, and the findings within this document should not be interpreted to be ICER’s final conclusions.
